

REMARKS

Status of the Claims

Claims 1-15 are currently pending in the present application. Claims 2-15 have been added. Support for the new claims may be found on pages 5-12 of the international application. No new matter is added by way of amendment.

The specification has been amended to identify the present application as a U.S. national stage filing of PCT/US2004/008301 and to substitute an abstract on a separate sheet in accordance with U.S. practice. It is believed that the current application is now in condition for examination. If, in the opinion of the Examiner, an interview would expedite prosecution, the Examiner is invited to call the undersigned agent.

Applicants believe that no fees are due in connection with the filing of this paper other than those specifically authorized herewith. However, should any other fees be deemed necessary to effect the timely filing of this paper the Commissioner is hereby authorized to charge such fees to Deposit Account No. 07-1392.

Respectfully submitted,



Kathryn L. Coulter
Patent Agent
Registration No. 45,889

Date: September 20, 2005
GlaxoSmithKline
Five Moore Drive, PO Box 13398
Research Triangle Park, North Carolina 27709
Telephone: (919) 483-1467
Facsimile: (919) 483-7988